Human Cancer Genetics, Spanish National Cancer Research Center (CNIO), C/Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Br J Cancer. 2013 Apr 30;108(8):1732-42. doi: 10.1038/bjc.2013.141. Epub 2013 Apr 4.
Few studies have attempted to characterise genomic changes occurring in hereditary epithelial ovarian carcinomas (EOCs) and inconsistent results have been obtained. Given the relevance of DNA copy number alterations in ovarian oncogenesis and growing clinical implications of the BRCA-gene status, we aimed to characterise the genomic profiles of hereditary and sporadic ovarian tumours.
High-resolution array Comparative Genomic Hybridisation profiling of 53 familial (21 BRCA1, 6 BRCA2 and 26 non-BRCA1/2) and 15 sporadic tumours in combination with supervised and unsupervised analysis was used to define common and/or specific copy number features.
Unsupervised hierarchical clustering did not stratify tumours according to their familial or sporadic condition or to their BRCA1/2 mutation status. Common recurrent changes, spanning genes potentially fundamental for ovarian carcinogenesis, regardless of BRCA mutations, and several candidate subtype-specific events were defined. Despite similarities, greater contribution of losses was revealed to be a hallmark of BRCA1 and BRCA2 tumours.
Somatic alterations occurring in the development of familial EOCs do not differ substantially from the ones occurring in sporadic carcinomas. However, some specific features like extensive genomic loss observed in BRCA1/2 tumours may be of clinical relevance helping to identify BRCA-related patients likely to respond to PARP inhibitors.
少数研究试图描述遗传性上皮性卵巢癌(EOC)中发生的基因组变化,但得到的结果不一致。鉴于 DNA 拷贝数改变在卵巢发生中的相关性以及 BRCA 基因状态的不断增长的临床意义,我们旨在描述遗传性和散发性卵巢肿瘤的基因组特征。
对 53 例家族性(21 例 BRCA1、6 例 BRCA2 和 26 例非 BRCA1/2)和 15 例散发性肿瘤进行高分辨率阵列比较基因组杂交分析,结合监督和非监督分析,以定义常见和/或特定的拷贝数特征。
非监督层次聚类不能根据肿瘤的家族性或散发性或 BRCA1/2 突变状态对肿瘤进行分层。定义了常见的复发性改变,跨越了可能对卵巢癌发生至关重要的基因,无论是否存在 BRCA 突变,并且还定义了几个候选的亚型特异性事件。尽管存在相似之处,但 BRCA1 和 BRCA2 肿瘤中更多的缺失贡献被揭示为其标志。
家族性 EOC 发生的体细胞改变与散发性癌中发生的改变没有实质性差异。然而,一些特定的特征,如在 BRCA1/2 肿瘤中观察到的广泛基因组缺失,可能具有临床意义,有助于识别可能对 PARP 抑制剂有反应的 BRCA 相关患者。